BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.60
+0.11 (1.47%)
Nov 22, 2024, 4:00 PM EST - Market closed
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 536 employees as of December 31, 2023. The number of employees increased by 5 or 0.94% compared to the previous year.
Employees
536
Change (1Y)
5
Growth (1Y)
0.94%
Revenue / Employee
$769,737
Profits / Employee
-$231,002
Market Cap
1.57B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Certara | 1,391 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
InMode | 581 |
Harrow | 315 |
Kiniksa Pharmaceuticals International, | 297 |
Neumora Therapeutics | 124 |
BCRX News
- 5 days ago - BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewsWire
- 17 days ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioCryst to Report Third Quarter 2024 Financial Results on November 4 - GlobeNewsWire
- 5 weeks ago - BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) - GlobeNewsWire
- 7 weeks ago - BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome - GlobeNewsWire
- 7 weeks ago - U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile - GlobeNewsWire